Alex Zhavoronkov, founder and co-chief executive of techbio company Insilico, is among the scientists who have devoted countless hours to studying aging. He has a reality-check for anyone who thinks that artificial intelligence means that the ability to double lifespans is tantalizingly close. “Absolute nonsense,” said Zhavoronkov, whose company uses AI to discover and develop drugs.In 150 years of discovery, no drug has been clinically proven to extend life, he said in an interview. “Regardless of how rich you are…you cannot buy one year of life with a drug.” What could be within reach in the next decade or so—in...